CLINICAL TRIALS PROFILE FOR OLICERIDINE
✉ Email this page to a colleague
All Clinical Trials for OLICERIDINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02656875 ↗ | A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain | Completed | Trevena Inc. | Phase 3 | 2015-12-01 | Patients with moderate to severe pain caused by medical conditions or surgery, who require IV opioid therapy may be enrolled in this open label safety study. Patients will be treated with TRV130 by IV bolus, PCA (patient-controlled analgesia) administration, or both, as determined by the investigator, for a duration not to exceed 14 days. |
| NCT02815709 ↗ | Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy | Completed | Trevena Inc. | Phase 3 | 2016-05-01 | The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine administered as needed (PRN) compared with placebo in patients with moderate to severe acute postoperative pain after bunionectomy. |
| NCT02820324 ↗ | Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty | Completed | Trevena Inc. | Phase 3 | 2016-05-01 | The primary objective is to evaluate the analgesic efficacy of intravenous (IV) oliceridine administered as needed (PRN) compared with placebo in patients with moderate to severe acute pain after abdominoplasty. |
| NCT04979247 ↗ | Intravenous Oliceridine and Opioid-related Complications | Recruiting | The Cleveland Clinic | Phase 3 | 2021-09-15 | The investigator will evaluate the side effects of oliceridine. |
| NCT05465226 ↗ | Oliceridine in Patients With Acute Burn Injuries | Not yet recruiting | Trevena Inc. | Phase 4 | 2022-08-01 | Pain after acute burn injury is complex with much still not understood. The primary mechanism is believed to be nociceptive, but is interwoven with aspects of somatogenic, neuropathic, and psychogenic pathways. As such, opioid receptor agonists are an essential component for pain management after burn injury. The majority of wound care and dressing changes are completed in non-intubated patients and rates of respiratory depression concerning. Oliceridine is a biased, selective MOR agonist approved for treatment of acute pain. To date there is no literature of use in patients with burn injuries. While it should be effective, efficacy and the potential for reduced adverse events need to be quantified. Current practice and guidelines, plead for better analgesia for patients with burn injuries. |
| NCT05465226 ↗ | Oliceridine in Patients With Acute Burn Injuries | Not yet recruiting | University of Tennessee | Phase 4 | 2022-08-01 | Pain after acute burn injury is complex with much still not understood. The primary mechanism is believed to be nociceptive, but is interwoven with aspects of somatogenic, neuropathic, and psychogenic pathways. As such, opioid receptor agonists are an essential component for pain management after burn injury. The majority of wound care and dressing changes are completed in non-intubated patients and rates of respiratory depression concerning. Oliceridine is a biased, selective MOR agonist approved for treatment of acute pain. To date there is no literature of use in patients with burn injuries. While it should be effective, efficacy and the potential for reduced adverse events need to be quantified. Current practice and guidelines, plead for better analgesia for patients with burn injuries. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OLICERIDINE
Condition Name
Clinical Trial Locations for OLICERIDINE
Trials by Country
Clinical Trial Progress for OLICERIDINE
Clinical Trial Phase
Clinical Trial Sponsors for OLICERIDINE
Sponsor Name
